Genomics knowledge and attitudes among European public health professionals: Results of a cross-sectional survey.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 18 09 2019
accepted: 07 03 2020
entrez: 3 4 2020
pubmed: 3 4 2020
medline: 8 7 2020
Statut: epublish

Résumé

The international public health (PH) community is debating the opportunity to incorporate genomic technologies into PH practice. A survey was conducted to assess attitudes of the European Public Health Association (EUPHA) members towards their role in the implementation of public health genomics (PHG), and their knowledge and attitudes towards genetic testing and the delivery of genetic services. EUPHA members were invited via monthly newsletter and e-mail to take part in an online survey from February 2017 to January 2018. A descriptive analysis of knowledge and attitudes was conducted, along with a univariate and multivariate analysis of their determinants. Five hundred and two people completed the questionnaire, 17.9% were involved in PHG activities. Only 28.9% correctly identified all medical conditions for which there is (or not) evidence for implementing genetic testing; over 60% thought that investing in genomics may divert economic resources from social and environmental determinants of health. The majority agreed that PH professionals may play different roles in incorporating genomics into their activities. Better knowledge was associated with positive attitudes towards the use of genetic testing and the delivery of genetic services in PH (OR = 1.48; 95% CI 1.01-2.18). Our study revealed quite positive attitudes, but also a need to increase awareness on genomics among European PH professionals. Those directly involved in PHG activities tend to have a more positive attitude and better knowledge; however, gaps are also evident in this group, suggesting the need to harmonize practice and encourage greater exchange of knowledge among professionals.

Sections du résumé

BACKGROUND
The international public health (PH) community is debating the opportunity to incorporate genomic technologies into PH practice. A survey was conducted to assess attitudes of the European Public Health Association (EUPHA) members towards their role in the implementation of public health genomics (PHG), and their knowledge and attitudes towards genetic testing and the delivery of genetic services.
METHODS
EUPHA members were invited via monthly newsletter and e-mail to take part in an online survey from February 2017 to January 2018. A descriptive analysis of knowledge and attitudes was conducted, along with a univariate and multivariate analysis of their determinants.
RESULTS
Five hundred and two people completed the questionnaire, 17.9% were involved in PHG activities. Only 28.9% correctly identified all medical conditions for which there is (or not) evidence for implementing genetic testing; over 60% thought that investing in genomics may divert economic resources from social and environmental determinants of health. The majority agreed that PH professionals may play different roles in incorporating genomics into their activities. Better knowledge was associated with positive attitudes towards the use of genetic testing and the delivery of genetic services in PH (OR = 1.48; 95% CI 1.01-2.18).
CONCLUSIONS
Our study revealed quite positive attitudes, but also a need to increase awareness on genomics among European PH professionals. Those directly involved in PHG activities tend to have a more positive attitude and better knowledge; however, gaps are also evident in this group, suggesting the need to harmonize practice and encourage greater exchange of knowledge among professionals.

Identifiants

pubmed: 32240206
doi: 10.1371/journal.pone.0230749
pii: PONE-D-19-26230
pmc: PMC7117699
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0230749

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Eur J Hum Genet. 2011 Apr;19 Suppl 1:S6-44
pubmed: 21412252
J Community Genet. 2014 Oct;5(4):337-47
pubmed: 24895224
Am J Med Genet A. 2003 Jul 1;120A(1):63-71
pubmed: 12794694
Lancet. 2018 Oct 27;392(10157):1504
pubmed: 30496048
Eur J Hum Genet. 2018 Apr;26(4):518-526
pubmed: 29374276
QJM. 2014 Feb;107(2):93-7
pubmed: 24049051
BMC Med Educ. 2019 Jan 11;19(1):19
pubmed: 30635068
Public Health Genomics. 2014;17(4):209-20
pubmed: 24852571
J Community Genet. 2011 Mar;2(1):1-11
pubmed: 22109718
BMC Health Serv Res. 2014 May 28;14:239
pubmed: 24885316
Public Health Genomics. 2012;15(3-4):118-24
pubmed: 22488453
Am J Prev Med. 2007 Oct;33(4):310-7
pubmed: 17888858
Public Health Genomics. 2019;22(5-6):208-214
pubmed: 31805565
Public Health Genomics. 2012;15(6):327-34
pubmed: 22986915
N Engl J Med. 2002 Dec 5;347(23):1867-75
pubmed: 12466512
Genet Med. 2018 Oct;20(10):1131-1144
pubmed: 29300371
Genet Med. 2016 Dec;18(12):1171-1180
pubmed: 27906166
Ann Ig. 2017 Sep-Oct;29(5):464-480
pubmed: 28715059
Public Health Genomics. 2012;15(1):34-45
pubmed: 21734357
Front Public Health. 2017 Aug 22;5:223
pubmed: 28879178
Am J Prev Med. 2011 Apr;40(4):486-93
pubmed: 21406285
Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):45-50
pubmed: 26499415
Genet Test Mol Biomarkers. 2013 Mar;17(3):219-25
pubmed: 23390885
Int J Epidemiol. 2006 Jun;35(3):562-71
pubmed: 16540539
Eur J Hum Genet. 2018 May;26(5):605-615
pubmed: 29422659
Genet Med. 2015 Jan;17(1):63-7
pubmed: 24946156
Eur J Public Health. 2011 Feb;21(1):2-3
pubmed: 21247866
Eur J Public Health. 2014 Dec;24(6):877-9
pubmed: 25168910
Genet Med. 2007 Aug;9(8):496-503
pubmed: 17700387
Prev Chronic Dis. 2005 Apr;2(2):A05
pubmed: 15888216
Eur J Public Health. 2014 Jun;24(3):349-50
pubmed: 24860145
Prev Med. 2013 Nov;57(5):477-82
pubmed: 23827720
Front Genet. 2019 Jun 19;10:552
pubmed: 31275354
N Engl J Med. 2018 Oct 11;379(15):1398-1400
pubmed: 30184442
Am J Prev Med. 2011 Jan;40(1):61-6
pubmed: 21146769
Public Health Genomics. 2009;12(4):216-24
pubmed: 19367090
Eur J Hum Genet. 2010 Sep;18(9):972-7
pubmed: 20442748
Eur J Hum Genet. 2015 Jun;23(6):729-35
pubmed: 25248395
Genet Med. 2010 Dec;12(12):785-91
pubmed: 21189494
Eur J Public Health. 2017 Oct 1;27(5):931-937
pubmed: 27687585
Genet Med. 2018 Jun;20(6):574-582
pubmed: 29240076

Auteurs

Annalisa Rosso (A)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Local Health Unit-Azienda Sanitaria Locale Roma 2, Rome, Italy.

Erica Pitini (E)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Elvira D'Andrea (E)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States of America.

Marco Di Marco (M)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Local Health Unit Azienda Sanitaria Locale Roma 1, Rome, Italy.

Brigid Unim (B)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Valentina Baccolini (V)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Corrado De Vito (C)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Carolina Marzuillo (C)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Floris Barnhoorn (F)

European Public Health Association (EUPHA), Utrecht, the Netherlands.

Dineke Zeegers Paget (D)

European Public Health Association (EUPHA), Utrecht, the Netherlands.

Paolo Villari (P)

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH